PAN-301-1

N/A

Report date: 2023/12/01 20:06:44

Base Information

Drug NamePAN-301-1
Drug Alias NamePAN301-1SNS-301PAN-3011
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulantsAnti-ASPH
TargetsAspartyl (asparaginyl) β-hydroxylase
Therapy Area/IndicationsMyelodysplastic SyndromesProstatic NeoplasmsSquamous Cell Carcinoma of Head and Neck +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPanacea Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSensei Biotherapeutics Inc
Active IndicationsN/A
Inactive IndicationsMyelodysplastic SyndromesProstatic NeoplasmsSquamous Cell Carcinoma of Head and Neck +[4] 

Other Information

ATC CodeN/A
Related LinksN/A